GuoLine Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History

GuoLine Advisory’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$51M	Hold	67,300	–	–	4.39%	8
2026 Q2	$42M	Hold	67,300	–	–	3.91%	8
2026 Q1	$52M	Hold	67,300	–	–	5.44%	5
2025 Q4	$51.9M	Hold	67,300	–	–	4.78%	5
2025 Q3	$37.8M	Hold	67,300	–	–	3.77%	10
2025 Q2	$35.3M	Buy	67,300 +11,000	+20%	+$6.14M	3.75%	11
2025 Q1	$35.7M	Buy	56,300 +9,940	+21%	+$6.84M	3.78%	12
2024 Q4	$33M	Buy	46,360 +14,300	+45%	+$12M	3.41%	13
2024 Q3	$33.7M	Hold	32,060	–	–	3.43%	16
2024 Q2	$33.7M	Buy	32,060 +6,160	+24%	+$5.97M	3.6%	16
2024 Q1	$24.9M	Buy	+25,900	New	+$24.6M	3.04%	18

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

MCI

McDonald Capital Investors Orinda, California $1.22B AUM 4.07% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

GuoLine Advisory's REGN Position: Q3 2026 in Review

GuoLine Advisory held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2026 at 67,300 shares worth $51M. The position accounts for 4.39% of the portfolio, ranked #8.

GuoLine Advisory first reported a position in REGN in Q1 2024 and has held it in 11 quarters since. The position peaked at $52M in Q1 2026. 535 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

GuoLine Advisory held 67,300 shares of Regeneron Pharmaceuticals worth $51M as of Q3 2026.
GuoLine Advisory left its Regeneron Pharmaceuticals share count unchanged in Q3 2026.
Regeneron Pharmaceuticals made up 4.39% of GuoLine Advisory's portfolio in Q3 2026, its #8 holding.
GuoLine Advisory first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 11 quarters since.
GuoLine Advisory's Regeneron Pharmaceuticals position peaked at $52M in Q1 2026.
535 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on GuoLine Advisory's 13F filing for Q3 2026, filed 6 Oct 2026.